| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phosphotransferases (Alcohol Group Acceptor) | 22 | 2020 | 201 | 4.030 |
Why?
|
| Adamantane | 16 | 2017 | 40 | 3.210 |
Why?
|
| Pyridines | 22 | 2017 | 261 | 3.090 |
Why?
|
| Acyltransferases | 8 | 2010 | 40 | 2.220 |
Why?
|
| Antineoplastic Agents | 16 | 2015 | 1070 | 1.990 |
Why?
|
| Enzyme Inhibitors | 10 | 2012 | 659 | 1.490 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2016 | 90 | 1.150 |
Why?
|
| Cell Line, Tumor | 25 | 2016 | 1851 | 1.060 |
Why?
|
| Pyrroles | 3 | 2011 | 83 | 0.810 |
Why?
|
| Benzenesulfonates | 8 | 2011 | 30 | 0.770 |
Why?
|
| Ceramidases | 2 | 2011 | 47 | 0.740 |
Why?
|
| Mitosis | 2 | 2011 | 76 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 332 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 5 | 2010 | 87 | 0.630 |
Why?
|
| Mice | 30 | 2017 | 8474 | 0.620 |
Why?
|
| Fluorescent Dyes | 2 | 2010 | 191 | 0.570 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2016 | 1 | 0.560 |
Why?
|
| Palmitic Acid | 2 | 2007 | 51 | 0.560 |
Why?
|
| Apoptosis | 16 | 2017 | 1641 | 0.560 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 331 | 0.540 |
Why?
|
| Cell Proliferation | 14 | 2017 | 1174 | 0.540 |
Why?
|
| Lipoproteins | 2 | 2007 | 161 | 0.530 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 34 | 0.510 |
Why?
|
| Animals | 36 | 2017 | 20881 | 0.490 |
Why?
|
| Thiazolidinediones | 3 | 2009 | 77 | 0.480 |
Why?
|
| Isoenzymes | 2 | 2012 | 308 | 0.470 |
Why?
|
| Peptides | 2 | 2007 | 455 | 0.460 |
Why?
|
| Down-Regulation | 1 | 2015 | 447 | 0.460 |
Why?
|
| Humans | 70 | 2020 | 68618 | 0.460 |
Why?
|
| Autophagy | 3 | 2017 | 208 | 0.450 |
Why?
|
| Phenylurea Compounds | 9 | 2016 | 31 | 0.450 |
Why?
|
| Niacinamide | 9 | 2016 | 31 | 0.440 |
Why?
|
| Neoplasms | 5 | 2017 | 1667 | 0.420 |
Why?
|
| Lipoylation | 2 | 2010 | 8 | 0.420 |
Why?
|
| Mice, Inbred BALB C | 7 | 2011 | 532 | 0.410 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 332 | 0.410 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 163 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2015 | 304 | 0.390 |
Why?
|
| Kidney Neoplasms | 3 | 2015 | 206 | 0.380 |
Why?
|
| Quinolones | 1 | 2011 | 60 | 0.370 |
Why?
|
| Ceramides | 4 | 2015 | 578 | 0.370 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 475 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 468 | 0.360 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 334 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2016 | 756 | 0.350 |
Why?
|
| Pyrimidines | 1 | 2011 | 178 | 0.350 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 778 | 0.340 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 118 | 0.340 |
Why?
|
| Neoplasm Transplantation | 6 | 2010 | 160 | 0.340 |
Why?
|
| Blotting, Western | 6 | 2012 | 954 | 0.330 |
Why?
|
| Sphingosine | 8 | 2015 | 315 | 0.330 |
Why?
|
| Lysophospholipids | 7 | 2015 | 209 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 235 | 0.320 |
Why?
|
| Drug Synergism | 6 | 2016 | 260 | 0.320 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2011 | 111 | 0.320 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 72 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 7 | 2016 | 852 | 0.300 |
Why?
|
| Phosphorylation | 8 | 2016 | 1200 | 0.290 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 53 | 0.290 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 89 | 0.290 |
Why?
|
| Device Removal | 1 | 2008 | 100 | 0.290 |
Why?
|
| Equipment Design | 1 | 2008 | 500 | 0.280 |
Why?
|
| RNA, Small Interfering | 6 | 2011 | 434 | 0.270 |
Why?
|
| Structure-Activity Relationship | 4 | 2011 | 420 | 0.270 |
Why?
|
| Molecular Structure | 4 | 2011 | 397 | 0.260 |
Why?
|
| Ventilator Weaning | 2 | 2002 | 27 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2020 | 94 | 0.240 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2002 | 101 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 290 | 0.240 |
Why?
|
| Transfection | 4 | 2011 | 782 | 0.240 |
Why?
|
| Acetanilides | 1 | 2004 | 9 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2010 | 411 | 0.230 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 56 | 0.230 |
Why?
|
| Quinolines | 1 | 2004 | 48 | 0.230 |
Why?
|
| Pyrazines | 1 | 2004 | 46 | 0.230 |
Why?
|
| Molecular Docking Simulation | 2 | 2015 | 78 | 0.230 |
Why?
|
| Palmitoyl Coenzyme A | 1 | 2003 | 11 | 0.230 |
Why?
|
| Female | 24 | 2017 | 38074 | 0.230 |
Why?
|
| Mice, SCID | 4 | 2015 | 238 | 0.220 |
Why?
|
| Aorta, Thoracic | 3 | 1996 | 211 | 0.220 |
Why?
|
| Cell Cycle | 3 | 2010 | 312 | 0.220 |
Why?
|
| Carrier Proteins | 1 | 2006 | 597 | 0.220 |
Why?
|
| Models, Molecular | 3 | 2012 | 546 | 0.210 |
Why?
|
| Total Quality Management | 1 | 2002 | 45 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2011 | 174 | 0.200 |
Why?
|
| Infant | 17 | 2013 | 2891 | 0.200 |
Why?
|
| Signal Transduction | 7 | 2015 | 2689 | 0.200 |
Why?
|
| Quinacrine | 2 | 2011 | 10 | 0.200 |
Why?
|
| Cell Line | 4 | 2017 | 1752 | 0.190 |
Why?
|
| Reperfusion Injury | 3 | 2013 | 320 | 0.190 |
Why?
|
| Infant, Newborn | 13 | 2013 | 2455 | 0.190 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2011 | 65 | 0.190 |
Why?
|
| Peptide Fragments | 1 | 2003 | 483 | 0.190 |
Why?
|
| Kinetics | 3 | 2009 | 1047 | 0.190 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2010 | 175 | 0.180 |
Why?
|
| Herpesvirus 8, Human | 2 | 2017 | 24 | 0.180 |
Why?
|
| Male | 23 | 2017 | 37321 | 0.180 |
Why?
|
| Biological Assay | 1 | 2020 | 88 | 0.180 |
Why?
|
| Benzylidene Compounds | 2 | 2009 | 16 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 307 | 0.170 |
Why?
|
| Caspase 3 | 2 | 2010 | 233 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 282 | 0.160 |
Why?
|
| Child | 17 | 2013 | 6405 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1745 | 0.160 |
Why?
|
| Deoxycytidine | 2 | 2016 | 83 | 0.160 |
Why?
|
| Cell Nucleus | 3 | 2015 | 305 | 0.160 |
Why?
|
| Esophagus | 3 | 1997 | 303 | 0.160 |
Why?
|
| Cell Survival | 3 | 2016 | 901 | 0.150 |
Why?
|
| Microscopy, Confocal | 2 | 2010 | 337 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2011 | 114 | 0.150 |
Why?
|
| Fluorescence Polarization | 1 | 2017 | 14 | 0.150 |
Why?
|
| Molecular Probes | 1 | 2017 | 27 | 0.140 |
Why?
|
| Algorithms | 2 | 2002 | 1196 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 48 | 0.140 |
Why?
|
| Acetylation | 1 | 2016 | 94 | 0.140 |
Why?
|
| Esophageal Fistula | 1 | 1996 | 7 | 0.140 |
Why?
|
| Liver | 2 | 2012 | 1118 | 0.140 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 75 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 77 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 20 | 0.130 |
Why?
|
| Child, Preschool | 11 | 2013 | 3187 | 0.130 |
Why?
|
| Fistula | 1 | 1996 | 29 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 39 | 0.130 |
Why?
|
| RNA | 1 | 2017 | 171 | 0.130 |
Why?
|
| Histones | 1 | 2016 | 111 | 0.130 |
Why?
|
| RNA, Messenger | 4 | 2011 | 1664 | 0.130 |
Why?
|
| Foreign Bodies | 1 | 1996 | 58 | 0.130 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 27 | 0.130 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 20 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2015 | 117 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 215 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 1996 | 113 | 0.120 |
Why?
|
| Telomerase | 1 | 2015 | 85 | 0.120 |
Why?
|
| Hepatocytes | 2 | 2013 | 205 | 0.120 |
Why?
|
| Esophageal Stenosis | 3 | 1997 | 36 | 0.120 |
Why?
|
| Fluorouracil | 2 | 2011 | 130 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 2791 | 0.120 |
Why?
|
| Tracheal Stenosis | 2 | 1991 | 21 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2011 | 1536 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 2 | 2011 | 196 | 0.120 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2013 | 7 | 0.120 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 40 | 0.110 |
Why?
|
| Time Factors | 4 | 2007 | 4655 | 0.110 |
Why?
|
| Adolescent | 11 | 2013 | 8912 | 0.110 |
Why?
|
| Tetracycline | 1 | 2013 | 29 | 0.110 |
Why?
|
| Calcium Channels | 1 | 2013 | 59 | 0.110 |
Why?
|
| Trans-Activators | 2 | 2010 | 237 | 0.110 |
Why?
|
| Abdomen, Acute | 1 | 2013 | 14 | 0.110 |
Why?
|
| Doxycycline | 1 | 2013 | 49 | 0.110 |
Why?
|
| Critical Pathways | 1 | 2013 | 33 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 306 | 0.110 |
Why?
|
| Minocycline | 1 | 2013 | 61 | 0.110 |
Why?
|
| Ovarian Cysts | 1 | 1992 | 9 | 0.110 |
Why?
|
| Appendectomy | 1 | 2013 | 47 | 0.110 |
Why?
|
| NF-kappa B | 3 | 2012 | 432 | 0.110 |
Why?
|
| Melanoma | 2 | 2008 | 335 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2011 | 114 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 49 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2011 | 489 | 0.110 |
Why?
|
| Appendicitis | 1 | 2013 | 55 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2011 | 250 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1992 | 79 | 0.100 |
Why?
|
| Fetal Diseases | 1 | 1992 | 64 | 0.100 |
Why?
|
| Arthritis, Experimental | 1 | 2012 | 38 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2012 | 99 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2012 | 234 | 0.100 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 35 | 0.100 |
Why?
|
| Histamine | 1 | 2012 | 52 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.100 |
Why?
|
| Disease Progression | 1 | 2015 | 1038 | 0.100 |
Why?
|
| Dextran Sulfate | 2 | 2010 | 88 | 0.100 |
Why?
|
| Intellectual Disability | 1 | 1992 | 114 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 142 | 0.090 |
Why?
|
| Stereoisomerism | 1 | 2011 | 169 | 0.090 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 68 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2011 | 53 | 0.090 |
Why?
|
| Sternum | 1 | 1990 | 19 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2013 | 287 | 0.090 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2010 | 3 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 2 | 1993 | 318 | 0.090 |
Why?
|
| Caspase 7 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Catechols | 1 | 2010 | 14 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2011 | 19 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2015 | 122 | 0.090 |
Why?
|
| DNA Fragmentation | 1 | 2010 | 85 | 0.090 |
Why?
|
| Hamartoma | 1 | 2010 | 24 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 65 | 0.090 |
Why?
|
| Leupeptins | 1 | 2010 | 23 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 231 | 0.090 |
Why?
|
| Adenine | 1 | 2010 | 46 | 0.090 |
Why?
|
| Pleural Neoplasms | 1 | 2009 | 7 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2010 | 38 | 0.090 |
Why?
|
| Biological Availability | 1 | 2010 | 79 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 272 | 0.090 |
Why?
|
| ras Proteins | 2 | 2011 | 102 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2009 | 21 | 0.090 |
Why?
|
| Mitochondrial Membranes | 1 | 2010 | 45 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 22 | 0.090 |
Why?
|
| Unfolded Protein Response | 1 | 2010 | 70 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 1989 | 36 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 1989 | 24 | 0.080 |
Why?
|
| Abdominal Muscles | 2 | 1986 | 25 | 0.080 |
Why?
|
| Pancreatic Cyst | 1 | 1989 | 16 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 626 | 0.080 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cell-Free System | 1 | 2009 | 43 | 0.080 |
Why?
|
| Colitis | 1 | 2010 | 156 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2013 | 7277 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2012 | 400 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 2083 | 0.080 |
Why?
|
| Intestines | 1 | 1989 | 114 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 214 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 492 | 0.080 |
Why?
|
| Abdominal Injuries | 1 | 1989 | 60 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2009 | 122 | 0.080 |
Why?
|
| Cell Movement | 1 | 2011 | 630 | 0.080 |
Why?
|
| Rats | 3 | 2013 | 5300 | 0.080 |
Why?
|
| Drainage | 1 | 1989 | 133 | 0.080 |
Why?
|
| Equipment Safety | 1 | 2008 | 50 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2008 | 53 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 772 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2015 | 1692 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2008 | 112 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 299 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 498 | 0.070 |
Why?
|
| Vinblastine | 1 | 2007 | 40 | 0.070 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 40 | 0.070 |
Why?
|
| Colchicine | 1 | 2007 | 48 | 0.070 |
Why?
|
| Cell Division | 2 | 2009 | 541 | 0.070 |
Why?
|
| Tubulin | 1 | 2007 | 60 | 0.070 |
Why?
|
| Proteins | 1 | 2010 | 474 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 2005 | 189 | 0.070 |
Why?
|
| Pancreatitis | 1 | 1989 | 279 | 0.070 |
Why?
|
| Hernia, Umbilical | 1 | 1986 | 10 | 0.070 |
Why?
|
| Respiratory Paralysis | 1 | 1986 | 10 | 0.070 |
Why?
|
| Protein Transport | 1 | 2007 | 280 | 0.070 |
Why?
|
| Diaphragmatic Eventration | 1 | 1986 | 9 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 2550 | 0.070 |
Why?
|
| Cattle | 1 | 2007 | 475 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 561 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 346 | 0.070 |
Why?
|
| Myristic Acids | 1 | 2005 | 3 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2005 | 20 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 160 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2005 | 25 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 159 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2005 | 91 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 173 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 200 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2010 | 118 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2005 | 246 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 261 | 0.060 |
Why?
|
| Mutation | 2 | 2011 | 1213 | 0.060 |
Why?
|
| RNA Interference | 1 | 2005 | 266 | 0.060 |
Why?
|
| Reoperation | 3 | 1996 | 467 | 0.060 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2004 | 24 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2017 | 7029 | 0.060 |
Why?
|
| Radiography | 3 | 1997 | 572 | 0.060 |
Why?
|
| Half-Life | 1 | 2004 | 96 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2008 | 3259 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 3 | 2012 | 247 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.060 |
Why?
|
| Base Sequence | 1 | 2005 | 1015 | 0.060 |
Why?
|
| South Carolina | 5 | 2002 | 2752 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2004 | 238 | 0.060 |
Why?
|
| Burns | 1 | 2004 | 83 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 92 | 0.060 |
Why?
|
| Cytokines | 1 | 2007 | 866 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2017 | 765 | 0.060 |
Why?
|
| Colon | 2 | 2010 | 168 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2001 | 169 | 0.050 |
Why?
|
| Protein Binding | 2 | 2017 | 1027 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2324 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2010 | 331 | 0.050 |
Why?
|
| Catheterization | 2 | 1996 | 209 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1447 | 0.050 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2013 | 41 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2008 | 2358 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 362 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 2007 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 170 | 0.050 |
Why?
|
| Mitochondria, Liver | 2 | 2013 | 148 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 306 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 1996 | 1615 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 114 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1173 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2001 | 172 | 0.050 |
Why?
|
| Cell Death | 2 | 2011 | 329 | 0.050 |
Why?
|
| K562 Cells | 2 | 2010 | 44 | 0.040 |
Why?
|
| Pediatric Assistants | 1 | 1979 | 3 | 0.040 |
Why?
|
| Hospital Departments | 1 | 1979 | 15 | 0.040 |
Why?
|
| Wilms Tumor | 2 | 1994 | 47 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 737 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 1980 | 65 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 1979 | 19 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2012 | 682 | 0.040 |
Why?
|
| Physician Assistants | 1 | 1979 | 47 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2011 | 294 | 0.040 |
Why?
|
| Microscopy, Electron | 2 | 2017 | 351 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 216 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 411 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2010 | 753 | 0.040 |
Why?
|
| Length of Stay | 2 | 2013 | 780 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 1979 | 281 | 0.040 |
Why?
|
| Adult | 6 | 2017 | 21403 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 60 | 0.040 |
Why?
|
| Tracheoesophageal Fistula | 1 | 1997 | 15 | 0.040 |
Why?
|
| Nausea | 1 | 2017 | 47 | 0.040 |
Why?
|
| Vomiting | 1 | 2017 | 56 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 132 | 0.040 |
Why?
|
| Esophageal Diseases | 2 | 1994 | 95 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 1033 | 0.030 |
Why?
|
| Animal Welfare | 1 | 1996 | 11 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2013 | 311 | 0.030 |
Why?
|
| Credentialing | 1 | 1996 | 23 | 0.030 |
Why?
|
| Fatigue | 1 | 2017 | 132 | 0.030 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 136 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1996 | 49 | 0.030 |
Why?
|
| Research Personnel | 1 | 1996 | 83 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 183 | 0.030 |
Why?
|
| Inflammation | 2 | 2012 | 1030 | 0.030 |
Why?
|
| General Surgery | 1 | 1996 | 95 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2015 | 58 | 0.030 |
Why?
|
| Leukemia | 2 | 2009 | 117 | 0.030 |
Why?
|
| Genes, Wilms Tumor | 1 | 1994 | 5 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 2 | 1997 | 124 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 185 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1994 | 66 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 1994 | 43 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1994 | 59 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 1993 | 38 | 0.030 |
Why?
|
| Software | 1 | 1996 | 418 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 46 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 39 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 67 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 1026 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1993 | 57 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 100 | 0.030 |
Why?
|
| Hypoxia | 1 | 2013 | 169 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 150 | 0.030 |
Why?
|
| Leukocyte Rolling | 1 | 2012 | 2 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2013 | 88 | 0.030 |
Why?
|
| Leukocytes | 1 | 2012 | 99 | 0.030 |
Why?
|
| Propylene Glycols | 1 | 2012 | 16 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1994 | 271 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1993 | 123 | 0.030 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2012 | 24 | 0.030 |
Why?
|
| P-Selectin | 1 | 2012 | 16 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2012 | 94 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 45 | 0.030 |
Why?
|
| Chemokines | 1 | 2012 | 119 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 114 | 0.020 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2012 | 63 | 0.020 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 19 | 0.020 |
Why?
|
| Camptothecin | 1 | 2011 | 39 | 0.020 |
Why?
|
| Iron | 1 | 2013 | 197 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 64 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 199 | 0.020 |
Why?
|
| Gene Expression | 1 | 1994 | 770 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 78 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 155 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 453 | 0.020 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2010 | 32 | 0.020 |
Why?
|
| Esophageal Atresia | 1 | 1990 | 8 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2010 | 51 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2011 | 201 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 69 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2010 | 28 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 56 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 1990 | 34 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 142 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1990 | 75 | 0.020 |
Why?
|
| Hospitals, Special | 1 | 1990 | 15 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1994 | 364 | 0.020 |
Why?
|
| G1 Phase | 1 | 2009 | 42 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2009 | 59 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 499 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 1990 | 236 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 1994 | 700 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 231 | 0.020 |
Why?
|
| Pediatrics | 1 | 2013 | 341 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2009 | 19 | 0.020 |
Why?
|
| Recurrence | 1 | 1992 | 948 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 61 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Medical Oncology | 1 | 1990 | 110 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 705 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1989 | 109 | 0.020 |
Why?
|
| Esophagoplasty | 1 | 1988 | 9 | 0.020 |
Why?
|
| Burns, Chemical | 1 | 1988 | 7 | 0.020 |
Why?
|
| History, 19th Century | 1 | 1988 | 95 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 514 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1989 | 131 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2007 | 4 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 107 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1988 | 248 | 0.020 |
Why?
|
| Pregnancy | 1 | 1992 | 2334 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 89 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2673 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 1986 | 17 | 0.020 |
Why?
|
| Hernia, Ventral | 1 | 1986 | 35 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 219 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 5717 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 902 | 0.020 |
Why?
|
| Chickenpox | 1 | 1985 | 14 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.020 |
Why?
|
| Fasciitis | 1 | 1985 | 30 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 562 | 0.020 |
Why?
|
| Biological Dressings | 1 | 2004 | 4 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2008 | 254 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2004 | 32 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2004 | 111 | 0.020 |
Why?
|
| Hypothermia | 1 | 2004 | 37 | 0.020 |
Why?
|
| Age Factors | 1 | 1989 | 1864 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 2004 | 59 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 219 | 0.010 |
Why?
|
| Muscles | 1 | 1984 | 158 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1293 | 0.010 |
Why?
|
| Child Abuse | 1 | 2004 | 186 | 0.010 |
Why?
|
| Software Design | 1 | 2001 | 18 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 14862 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2001 | 190 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1980 | 14 | 0.010 |
Why?
|
| Role | 1 | 1979 | 25 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 21147 | 0.010 |
Why?
|
| Animals, Laboratory | 1 | 1996 | 21 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1980 | 371 | 0.010 |
Why?
|
| PAX8 Transcription Factor | 1 | 1994 | 2 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 1994 | 8 | 0.010 |
Why?
|
| PAX2 Transcription Factor | 1 | 1994 | 11 | 0.010 |
Why?
|
| Genes, Homeobox | 1 | 1994 | 15 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1994 | 95 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1994 | 76 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 1993 | 45 | 0.010 |
Why?
|
| Cholecystectomy | 1 | 1994 | 79 | 0.010 |
Why?
|
| Ulcer | 1 | 1993 | 27 | 0.010 |
Why?
|
| Esophagitis | 1 | 1993 | 45 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 672 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1991 | 951 | 0.010 |
Why?
|
| Necrosis | 1 | 1985 | 239 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1984 | 65 | 0.000 |
Why?
|
| Myosins | 1 | 1984 | 34 | 0.000 |
Why?
|
| Antibodies | 1 | 1984 | 241 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1984 | 1034 | 0.000 |
Why?
|